推进治疗前沿:用于UC管理的新药管道
Luisa Bertin1, Alessandro Massano1, Carlo Redavid1
1Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
Frontiers in gastroenterology (Lausanne, Switzerland)
|March 13, 2026
概括
新的性结肠炎治疗方法对中度至重度的疾病有希望. 新兴疗法针对新的途径,提供改善的缓解率和转向精准医学,以获得更好的患者结果.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症性肠病,其全球发病率正在增加.
- 目前对中度至重度UC的先进疗法存在局限性,反应率为30-60%,住院和切除术的比例很高.
- 对于有效的UC管理,仍有大量未满足的需求.
研究的目的:
- 对中度至重度性结肠炎的当前治疗环境和管道进行审查.
- 突出UC药物开发中的新兴机制和新目标.
- 讨论精准医学在改变UC治疗中的潜力.
主要方法:
- 对UC的II期和III期开发中的试验药物的临床试验数据的审查.
- 分析新兴的治疗机制,包括下一代抑制剂和途径调节器.
- 评估新型组合疗法方法和生物标志物引导的选择.
主要成果:
- 超过100种研究药物正在开发中度至重度UC.
- 有前途的新机制包括选择性IL-23抗剂和TNF类联结体1A抑制剂,早期试验显示了高缓解率.
- 组合疗法和肠选择性药物正在显示出优越的疗效和降低免疫抑制.
结论:
- 欧冠治疗管道是强大的,有不同的新兴策略.
- 针对特定途径的下一代疗法为改善患者结果提供了显著的潜力.
- 精准医学方法,包括生物标志物引导的选择和肠选择性化合物,即将彻底改变UC管理.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
589
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
589
Inflammatory Bowel Disease IV: Pharmacological Management
893
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
893
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
636
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
636
Inflammatory Bowel Disease V: Surgical Management
800
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
800
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
1.4K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.4K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
593
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
593


